Schrodinger, Inc.

Schrodinger, Inc. transforms how therapeutics and materials are discovered using a differentiated, physics-based computational platform. This platform enables the discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost compared to traditional methods. The company's software platform is licensed globally by biopharmaceutical and industrial companies, academic institutions, and government laboratories. Schrodinger applies its computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. Additionally, it uses its platform to discover novel molecules for its own pipeline of proprietary drug discovery programs, which are advanced through preclinical and clinical development. Traditional drug discovery is complex, lengthy, capital-intensive, and has high failure rates, relying on many iterations of costly and time-consuming manual molecule design, chemical synthesis, and experimental testing. Schrodinger's physics-based computational platform predicts critical properties of molecules with high accuracy, allowing drug discovery teams to design and selectively synthesize molecules with more optimal properties. This reduces the average time and costs to identify a development candidate and increases the probability of a program entering clinical development. The company believes development candidates with optimized property profiles have a higher probability of success in clinical development. Since the underlying physics for drug molecules and materials is the same, Schrodinger has extended its computational platform to materials science applications in fields such as aerospace, energy, semiconductors, electronic displays, and chemicals. The company offers various software solutions that accelerate all stages of molecule discovery, design, and optimization for its customers.